Biotech Values

[iwfal]

ISIS -

Part of the reason that ISIS has programs against targets that pharma does not is intentional - many have proven to be undruggable with small molecules (both diabetes and other therapeutic areas). SGLT2 was a notable exception, and proved to be a mistake.

Do you have any idea how assess this? What is small molecule accessible and what is not?

I also be interested in people's take on the Factor XI program - the preclinical data is pretty impressive to me. But I am not so thrilled that they are planning to run the phase 2 program themselves.

I'll look - but if they are wise they will keep a few promising drugs through ph ii for themselves. In particular I would suggest that they should keep the drugs which have such phenomenal benefit over SoC that even a small randomized ph ii should knock it out of the park. They may still need BP to take it through a huge safety clinical program.

PS Thanks for the R&D day slides.